one hundred ninety-five adult patients with refractory or first relapse acute myelogenous leukemia ( aml ) were randomly assigned to receive high-dose cytarabine ( hidac ) , 3 g/m2 as a three-hour intravenous ( iv ) infusion every 12 hours for four doses , followed by 6,000 iu/m2 asparaginase ( asnase ) administered at hour 42 , or hidac without asnase .
C0010711
cytarabine
C0278793
hidac